Patients with primary biliary cirrhosis have increased serum total antioxidant capacity measured with the crocin bleaching assay

Table 1 TAC and CTAC in patients and controls

Group	TAC (mmol/L)	CTAC (mmol/L)
Control	1.493 ± 0.059	0.797 ± 0.057
Cirrhotics	1.532 ± 0.095	0.723 ± 0.069
PBC	1.664 ± 0.062	1.012 ± 0.068
PBC I–II	1.691 ± 0.080	1.096 ± 0.077
PBC III–IV	1.593 ± 0.086	0.789 ± 0.117
CAH	1.477 ± 0.080	0.875 ± 0.072

Table 2 TAC and CTAC in PBC patients before and after UDCA treatment

Group		Before UDCA	After UDCA	Significance
PBC Total	TAC	1.697 ± 0.077	1.289 ± 0.093	< 0.001
	CTAC	1.068 ± 0.071	0.601 ± 0.093	< 0.001
PBC I–II	TAC	1.762 ± 0.082	1.243 ± 0.124	< 0.001
	CTAC	1.169 ± 0.076	0.660 ± 0.115	< 0.001
PBC III–IV	TAC	1.527 ± 0.184	1.410 ± 0.049	NS
	CTAC	0.789 ± 0.153	0.448 ± 0.091	NS

Table 3 TAC and CTAC in serum samples collected from hepatic and peripheral vein in cirrhotic and PBC patients

Group		Hepatic	Peripheral	Significance
Cirrhotics	TAC	1.357 ± 0.052	1.532 ± 0.095	< 0.05
	CTAC	0.563 ± 0.031	0.757 ± 0.073	< 0.05
PBC	TAC	1.494 ± 0.074	1.587 ± 0.071	NS
	CTAC	0.821 ± 0.032	0.913 ± 0.042	NS